Navigation Links
Proclear® Toric

ProductsProclear® Toric
Company CooperVision
Item Proclear® Toric
Features 
  • Exceptional all-day comfort
  • Outstanding vision quality
  • Patented PC Technology
  • Convenient monthly replacement schedule
Description Exceptional comfort for those with astigmatism.

If you have astigmatism, Proclear Toric soft contact lenses let you enjoy a level of comfort unrivaled by any other soft toric lensa difference youll especially notice the longer you wear your lenses throughout the day.

This exceptional level of comfort is made possible by PC Technology™, which creates a unique material containing molecules of phosphorylcholine (PC), a substance found naturally in human cell membranes. These molecules attract and surround themselves with water, keeping Proclear lenses moist and comfortable, even after 12 hours of wear.

Info CooperVision
Customer Service: (800) 341-2020
Web site: http://www.coopervision.com/

Related medicine products :

1. Proclear® Tailor Made Toric
2. Acuvue Toric
3. Optima Toric
4. Soflens66 Toric
5. Vertex Toric®
6. Frequency® 55 Toric
7. Frequency® 55 Toric XR
8. Hydrasoft® Toric
9. Preference® Toric
10. Focus Dailies Toric
11. Focus Toric Monthly lenses
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place.
Slim bronchoscope designed for paediatric applications.
...erformance fiberoptic imaging from the latest 60 s...ts fiberscope range, focussing on providing clinic...ge performance. Olympus has a impressive range of ...n the respiratory tract to meet the demands of inc...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation.
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...ved breast cancer twice, says that all women deser...at the life-saving and life-improving drug should ...rom this deadly cancer have a chance of successful... uniform policy and the drug is federally funded i...
...obbed off their pockets to pay for expensive anti-... the service based health care system, // believed... AIDS related symptoms when she was admitted to th...e bit of money she had, ensured prompt medical att...
...esia has been confirmed to be bird flu related as ...ncy, according to official sources. // If this wer...ognized testing centers, it would increase the Ind...2. 'We got the local test result around Friday. H...
...of the primary diseases affecting the children bel...asons. RSV infections start by the end of November... the month of December. // Deborah Lehman, MD, ass...diseases and HIV at Cedars-Sinai Medical Center sa...
Other Medicine News:Health News:AIDS Patients Deceived By Private Health Care System In China 2Health News:Parental Knowledge Of RSV Infections Is Vital 2
(Date:9/4/2008)... activity and favorable safety ...- Idenix,Pharmaceuticals, I...engaged,in the discovery and development of drugs ...ous diseases, today announced that it has complete...non-nucleoside reverse,transcriptase inhibitor (NN...
(Date:9/3/2008)...Call/ -- Simcere,Pharmaceutical Group (NYSE: SCR ...generic pharmaceuticals and manufacturer of the pa...n as Endostar) in China,announced the interim res...uest of the SFDA, Simcere initiated a Phase IV cli...rapeutic efficacy of Endu, a modified,version of r...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...Study in Subjects with ALS, RICHMOND, Calif., Sep..., Inc. (Nasdaq: SGMO ) announced today that it ha...evaluate its drug, SB-509, in subjects,with ALS, a...r which there,are limited treatment options and no...formulation of a plasmid,encoding a zinc finger DN...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib 28ZACTIMA 28R 29 29 in Non Small Cell Lung C 3903 1AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib 28ZACTIMA 28R 29 29 in Non Small Cell Lung C 3903 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib 28ZACTIMA 28R 29 29 in Non Small Cell Lung C 3903 3Omnicell Announces Completion of Its Common Stock Repurchase Plan 14121 1Omnicell Announces Completion of Its Common Stock Repurchase Plan 14121 2Chef LaLa to Provide Healthy Menu Makeovers 14117 1Chef LaLa to Provide Healthy Menu Makeovers 14117 2Chef LaLa to Provide Healthy Menu Makeovers 14117 3Chef LaLa to Provide Healthy Menu Makeovers 14117 4Chef LaLa to Provide Healthy Menu Makeovers 14117 5Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 3899 1Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 3899 2
...es support the development of DG041 as an,effectiv...sk, REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-...ress in the development of,DG041, the company,s Ph...f arterial thrombosis. The results of the Phase II...y build upon previous,findings demonstrating DG041...
...g,s Efficacy at Improving Glycemic Control and,Red...GO, Ill., June 23, 2007 /PRNewswire/ -- VeroScienc...partner S2 Therapeutics,Inc., reported today the ...g the overall and cardiovascular safety of Cyclose...e mesylate) in subjects,with type 2 diabetes. The ...
Other Medicine Technology:Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5